Effectiveness of transdermal nicotine patch in premenopausal female smokers is moderated by within-subject severity of negative affect and physical symptoms.


Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 17 09 2019
accepted: 19 02 2020
pubmed: 12 3 2020
medline: 30 9 2020
entrez: 12 3 2020
Statut: ppublish

Résumé

Nicotine patches may be less effective in female compared with male smokers. However, it is unknown if negative affect and physical symptoms influence transdermal nicotine patch-related effects on smoking behaviors. Eighty-one acutely tobacco-abstinent premenopausal female smokers attended three counter-balanced experimental sessions across the menstrual cycle (early follicular, late follicular, and mid-luteal) and were randomized to patch condition (nicotine [21 mg] vs. placebo [0 mg] transdermal patch). Negative affect and physical symptoms were assessed prior to patch administration. The patch was removed 5 h post-administration, and participants completed a smoking reinstatement task. Multilevel linear models tested associations of patch condition, negative affect and physical symptoms, and their interaction on smoking behavior. There was a significant patch condition × Negative Affect and Pain symptoms interaction on the number of cigarettes smoked (p < 0.05). When Negative Affect and Pain were lower-than-usual, females administered a nicotine patch smoked significantly fewer cigarettes than females administered a placebo patch (p < .05), but there were no significant patch differences when Negative Affect and Pain were higher-than-usual. There was also a significant patch condition × Negative Affect interaction on time delay. The effects of patch condition on time delay to smoking were greater during sessions in which Negative Affect was higher-than-usual. Results suggest that among female smokers transdermal nicotine patch effectiveness may interact with negative affect and pain. Understanding and considering female-specific factors that may impact the efficacy of one of the most commonly used cessation medications is important for improving smoking cessation in female smokers.

Identifiants

pubmed: 32157328
doi: 10.1007/s00213-020-05494-z
pii: 10.1007/s00213-020-05494-z
pmc: PMC7244386
mid: NIHMS1574608
doi:

Substances chimiques

Nicotine 6M3C89ZY6R

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1737-1744

Subventions

Organisme : NIDA NIH HHS
ID : K01 DA040043
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA034768
Pays : United States

Références

Allen SS, McBride CM, Pirie PL (1991) The shortened premenstrual assessment form. J Reprod Med 36:769–772
pubmed: 1765953
Allen SS, Hatsukami D, Christianson D, Brown S (2000) Effects of transdermal nicotine on craving, withdrawal and premenstrual symptomatology in short-term smoking abstinence during different phases of the menstrual cycle. Nicotine Tob Res 2:231–241
doi: 10.1080/14622200050147493
Allen SS, Bade T, Center B, Finstad D, Hatsukami D (2008) Menstrual phase effects on smoking relapse. Addiction 103:809–821
doi: 10.1111/j.1360-0443.2008.02146.x
Allen AM, Allen SS, Widenmier J, Al'absi M (2009a) Patterns of cortisol and craving by menstrual phase in women attempting to quit smoking. Addict Behav 34:632–635
doi: 10.1016/j.addbeh.2009.03.024
Allen SS, Allen AM, Pomerleau CS (2009b) Influence of phase-related variability in premenstrual symptomatology, mood, smoking withdrawal, and smoking behavior during ad libitum smoking, on smoking cessation outcome. Addict Behav 34:107–111
doi: 10.1016/j.addbeh.2008.08.009
Allenby CE, Boylan KA, Lerman C, Falcone M (2016) Precision medicine for tobacco dependence: development and validation of the nicotine metabolite ratio. J NeuroImmune Pharmacol 11:471–483
doi: 10.1007/s11481-016-9656-y
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Health Disorders. American Psychiatric Association, Washington
doi: 10.1176/appi.books.9780890425596
Bello MS, McBeth JF, Ditre JW, Kirkpatrick MG, Ray LA, Dunn KE, Leventhal AM (2018) Pain as a predictor and consequence of tobacco abstinence effects amongst African American smokers. J Abnorm Psychol 127:683–694
doi: 10.1037/abn0000367
Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P 3rd (2006) Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 79:480–488
doi: 10.1016/j.clpt.2006.01.008
Berlin I, Gasior MJ, Moolchan ET (2007) Sex-based and hormonal contraception effects on the metabolism of nicotine among adolescent tobacco-dependent smokers. Nicotine Tob Res 9:493–498
doi: 10.1080/14622200701243193
Bradizza CM, Stasiewicz PR, Zhuo Y, Ruszczyk M, Maisto SA, Lucke JF, Brandon TH, Eiden RD, Slosman KS, Giarratano P (2017) Smoking cessation for pregnant smokers: development and pilot test of an emotion regulation treatment supplement to standard smoking cessation for negative affect smokers. Nicotine Tob Res 19:578–584
doi: 10.1093/ntr/ntw398
Carpenter MJ, Saladin ME, Leinbach AS, Larowe SD, Upadhyaya HP (2008) Menstrual phase effects on smoking cessation: a pilot feasibility study. J Women's Health (Larchmt) 17:293–301
doi: 10.1089/jwh.2007.0415
Ditre JW, Heckman BW, Zale EL, Kosiba JD, Maisto SA (2016) Acute analgesic effects of nicotine and tobacco in humans: a meta-analysis. Pain 157:1373–1381
doi: 10.1097/j.pain.0000000000000572
Doran N (2014) Sex differences in smoking cue reactivity: craving, negative affect, and preference for immediate smoking. Am J Addict 23:211–217
doi: 10.1111/j.1521-0391.2014.12094.x
Eisenlohr-Moul TA, Girdler SS, Schmalenberger KM, Dawson DN, Surana P, Johnson JL, Rubinow DR (2017) Toward the reliable diagnosis of DSM-5 premenstrual dysphoric disorder: the Carolina Premenstrual Assessment Scoring System (C-PASS). Am J Psychiatry 174:51–59
doi: 10.1176/appi.ajp.2016.15121510
Eisenlohr-Moul TA, Kaiser G, Weise C, Schmalenberger KM, Kiesner J, Ditzen B, Kleinstauber M (2019) Are there temporal subtypes of premenstrual dysphoric disorder?: using group-based trajectory modeling to identify individual differences in symptom change. Psychol Med:1–9
Epperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, Mazure CM, O'Malley SS (2010) Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug Alcohol Depend 112:1–8
doi: 10.1016/j.drugalcdep.2010.04.021
Fehring RJ, Schneider M, Raviele K (2006) Variability in the phases of the menstrual cycle. J Obstet Gynecol Neonatal Nurs 35:376–384
doi: 10.1111/j.1552-6909.2006.00051.x
Ferguson SG, Shiffman S (2014) Effect of high-dose nicotine patch on craving and negative affect leading up to lapse episodes. Psychopharmacology 231:2595–2602
doi: 10.1007/s00213-013-3429-6
Franklin TR, Allen SS (2009) Influence of menstrual cycle phase on smoking cessation treatment outcome: a hypothesis regarding the discordant findings in the literature. Addiction 104:1941–1942
doi: 10.1111/j.1360-0443.2009.02758.x
Franklin TR, Ehrman R, Lynch KG, Harper D, Sciortino N, O'Brien CP, Childress AR (2008) Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis. J Women's Health (Larchmt) 17:287–292
doi: 10.1089/jwh.2007.0423
Jao NC, Veluz-Wilkins AK, Smith MJ, Carroll AJ, Blazekovic S, Leone FT, Tyndale RF, Schnoll RA, Hitsman B (2017) Does menthol cigarette use moderate the effect of nicotine metabolism on short-term smoking cessation? Exp Clin Psychopharmacol 25:216–222
doi: 10.1037/pha0000124
Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George TP, Wileyto EP, Swan GE, Benowitz NL, Heitjan DF, Tyndale RF (2015) Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med 3:131–138
doi: 10.1016/S2213-2600(14)70294-2
Mazure CM, Toll B, McKee SA, Wu R, O'Malley SS (2011) Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion. Drug Alcohol Depend 114:68–72
doi: 10.1016/j.drugalcdep.2010.07.024
McKee SA (2009) Developing human laboratory models of smoking lapse behavior for medication screening. Addict Biol 14:99–107
doi: 10.1111/j.1369-1600.2008.00135.x
McKee SA, Smith PH, Kaufman M, Mazure CM, Weinberger AH (2015) Sex differences in varenicline efficacy for smoking cessation: a meta-analysis. Nicotine Tob Res
Messer S, Siegel A, Bertin L, Erblich J (2018) Sex differences in affect-triggered lapses during smoking cessation: a daily diary study. Addict Behav 87:82–85
doi: 10.1016/j.addbeh.2018.06.019
Mumford SL, Steiner AZ, Pollack AZ, Perkins NJ, Filiberto AC, Albert PS, Mattison DR, Wactawski-Wende J, Schisterman EF (2012) The utility of menstrual cycle length as an indicator of cumulative hormonal exposure. J Clin Endocrinol Metab 97:E1871–E1879
doi: 10.1210/jc.2012-1350
Pang RD, Leventhal AM (2013) Sex differences in negative affect and lapse behavior during acute tobacco abstinence: a laboratory study. Exp Clin Psychopharmacol 21:269–276
doi: 10.1037/a0033429
Pang RD, Andrabi N, Leventhal AM (2017a) Premenstrual symptoms and factors implicated in smoking cessation among woman smokers. Exp Clin Psychopharmacol 25:235–241
doi: 10.1037/pha0000132
Pang RD, Liautaud MM, Kirkpatrick MG, Huh J, Monterosso J, Leventhal AM (2017b) Ovarian hormones and transdermal nicotine administration independently and synergistically suppress tobacco withdrawal symptoms and smoking reinstatement in the human laboratory. Neuropsychopharmacology
Perkins KA, Scott J (2008) Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res 10:1245–1250
doi: 10.1080/14622200802097506
Perkins KA, Jacobs L, Sanders M, Caggiula AR (2002) Sex differences in the subjective and reinforcing effects of cigarette nicotine dose. Psychopharmacology 163:194–201
doi: 10.1007/s00213-002-1168-1
Smith PH, Kasza KA, Hyland A, Fong GT, Borland R, Brady K, Carpenter MJ, Hartwell K, Cummings KM, McKee SA (2015) Gender differences in medication use and cigarette smoking cessation: results from the International Tobacco Control Four Country Survey. Nicotine Tob Res 17:463–472
doi: 10.1093/ntr/ntu212
Smith PH, Weinberger AH, Zhang J, Emme E, Mazure CM, McKee SA (2016) Sex differences in smoking cessation pharmacotherapy comparative efficacy: a network meta-analysis. Nicotine Tob Res
Smith PH, Zhang J, Weinberger AH, Mazure CM, McKee SA (2017) Gender differences in the real-world effectiveness of smoking cessation medications: findings from the 2010-2011 Tobacco Use Supplement to the Current Population Survey. Drug Alcohol Depend 178:485–491
doi: 10.1016/j.drugalcdep.2017.05.046
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA (2015) Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence. Nicotine Tob Res 17:486–495
doi: 10.1093/ntr/ntu280
Weinberger AH, McKee SA (2012) Gender differences in smoking following an implicit mood induction. Nicotine Tob Res 14:621–625
doi: 10.1093/ntr/ntr198
Weinberger AH, Smith PH, Kaufman M, McKee SA (2014) Consideration of sex in clinical trials of transdermal nicotine patch: a systematic review. Exp Clin Psychopharmacol 22:373–383
doi: 10.1037/a0037692
Weinberger AH, Smith PH, Allen SS, Cosgrove KP, Saladin ME, Gray KM, Mazure CM, Wetherington CL, McKee SA (2015) Systematic and meta-analytic review of research examining the impact of menstrual cycle phase and ovarian hormones on smoking and cessation. Nicotine Tob Res 17:407–421
doi: 10.1093/ntr/ntu249
Wetherill RR, Franklin TR, Allen SS (2016) Ovarian hormones, menstrual cycle phase, and smoking: a review with recommendations for future studies. Current addiction reports 3:1–8
doi: 10.1007/s40429-016-0093-z
Widaman KF, Little TD, Preacher KJ, Sawalani GM (2011) On creating and using short forms of scales in secondary research secondary data analysis: an introduction for psychologists. American Psychological Association, Washington, pp 39–61
doi: 10.1037/12350-003

Auteurs

Stephanie H Chai (SH)

Department of Preventive Medicine, University of Southern California Keck School of Medicine, 2001 N Soto Street, 312E, Los Angeles, CA, 90032, USA.

Adam M Leventhal (AM)

Department of Preventive Medicine, University of Southern California Keck School of Medicine, 2001 N Soto Street, 312E, Los Angeles, CA, 90032, USA.
Department of Psychology, University of Southern California, Los Angeles, CA, USA.

Matthew G Kirkpatrick (MG)

Department of Preventive Medicine, University of Southern California Keck School of Medicine, 2001 N Soto Street, 312E, Los Angeles, CA, 90032, USA.

Tory A Eisenlohr-Moul (TA)

Department of Psychiatry, University of Illinois Chicago, Chicago, IL, USA.

Andrea J Rapkin (AJ)

Department of Obstetrics and Gynecology, Center for the Health Sciences, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.

Lina D'Orazio (L)

Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

Raina D Pang (RD)

Department of Preventive Medicine, University of Southern California Keck School of Medicine, 2001 N Soto Street, 312E, Los Angeles, CA, 90032, USA. rpang@usc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH